Tricida to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, May 8, 2019

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its
first quarter 2019 financial results after the close of market on
Wednesday, May 8, 2019. Tricida will host a conference call and webcast
at 4:30 pm Eastern Time to discuss its financial results and business
progress. The call or webcast may be accessed as follows:

A replay of the webcast will be available on Tricida’s website
approximately two hours following the completion of the call and will be
available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of its drug candidate, TRC101, a non-absorbed,
orally-administered polymer designed to treat metabolic acidosis in
patients with CKD. Metabolic acidosis is a condition commonly caused by
CKD that is believed to accelerate the progression of kidney
deterioration. It is estimated to pose a health risk to approximately
three million patients with CKD in the United States. Tricida has
successfully completed all of the clinical trials that it planned to
complete prior to submission of an NDA to the U.S. Food and Drug
Administration (FDA). Tricida plans to submit an NDA, in the second half
of 2019, seeking approval of TRC101 through the FDA’s Accelerated
Approval Program.

For more information about Tricida, please visit www.Tricida.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements, including for
example, statements about our ability to submit an NDA for TRC101 under
the FDA’s Accelerated Approval Program. Forward‐looking statements
involve known and unknown risks, uncertainties, assumptions and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward‐looking
statements. These risks and uncertainties include, among others, the
timing of Tricida’s NDA submission; that many drug candidates that have
completed Phase 3 trials do not become approved drugs on a timely or
cost effective basis or at all; there can be no assurance that the FDA
will find that our clinical trials have provided evidence of clinical
benefit; there can be no assurance that the FDA would approve an NDA
under the Accelerated Approval Program, or at all, and even if approval
for a drug is obtained, there can be no assurance that it will be
adopted in the market or accepted as a benefit to patients and
healthcare providers; possible safety and efficacy concerns; and that we
completely rely on third-party suppliers to manufacture TRC101. The
forward-looking statements contained in this press release reflect
Tricida’s current views with respect to future events, and Tricida does
not undertake and specifically disclaims any obligation to update any
forward-looking statements.

Contacts

Jackie Cossmon, IRC
Tricida, Inc.
Vice President of Investor
Relations and Communications
[email protected]